STOCK TITAN

Armistice Capital (CRIS) reports 1.34M shares, 9.99% ownership

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Curis Inc. Schedule 13G/A: Armistice Capital, LLC and Steven Boyd report beneficial ownership of 1,336,876 shares, representing 9.99% of Curis common stock as of 12/31/2025.

The filing states Armistice Capital exercises shared voting and dispositive power over those 1,336,876 shares; the Master Fund is the direct holder and may receive dividends or sale proceeds.

Positive

  • None.

Negative

  • None.

Insights

Armistice holds a near-10% stake with shared voting and dispositive power.

The filing records 1,336,876 shares (9.99%) beneficially owned as of 12/31/2025, with Armistice Capital exercising shared voting and dispositive power on behalf of the Master Fund.

This is a disclosure of ownership under Rule 13d; the Master Fund is noted as the direct holder and has rights to dividends or sale proceeds per Item 6. Subsequent filings would show any change in percent or voting power.

Position size is material for disclosure but not a controlling stake.

The reported 9.99% ownership threshold is below many control thresholds; the filing shows shared voting power 1,336,876 and identical shared dispositive power.

Because the Master Fund is the direct holder and Armistice is the manager, cash‑flow treatment (who receives proceeds) is linked to the Master Fund per Item 6; timing of any disposals or votes depends on future filings.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Armistice Capital, LLC
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd - Managing Member
Date:02/17/2026
Steven Boyd
Signature:/s/ Steven Boyd
Name/Title:Steven Boyd
Date:02/17/2026
Exhibit Information

JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: February 17, 2026 Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd - Managing Member Steven Boyd By: /s/ Steven Boyd

FAQ

What stake does Armistice Capital report in CRIS?

Armistice Capital reports beneficial ownership of 1,336,876 shares, equal to 9.99% of CRIS as of 12/31/2025. The filing attributes shared voting and shared dispositive power over those shares to Armistice Capital.

Who is the direct holder of the reported CRIS shares?

The direct holder is the Armistice Capital Master Fund Ltd., an investment advisory client of Armistice Capital. The Master Fund holds the shares while Armistice Capital exercises voting and investment power.

Does Steven Boyd personally own the reported CRIS shares?

Steven Boyd is listed as managing member of Armistice Capital and is reported as beneficially owning 1,336,876 shares with shared voting and dispositive power. Footnotes describe his relationship to Armistice and the Master Fund.

What voting and dispositive powers are disclosed for the CRIS stake?

The filing shows 0 sole voting/dispositive power and 1,336,876 shared voting and shared dispositive power for the reported shares. Those numbers are tied to the 1,336,876-share position.

Does the filing state who receives proceeds or dividends for the CRIS shares?

Yes; the filing states the Master Fund has the right to receive dividends or proceeds from sale of the reported securities. Item 6 identifies the Master Fund as entitled to those proceeds.
Curis

NASDAQ:CRIS

CRIS Rankings

CRIS Latest News

CRIS Latest SEC Filings

CRIS Stock Data

14.79M
12.02M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
LEXINGTON